FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029689076> ?p ?o ?g. }

• W2029689076 endingPage "18" @default.
• W2029689076 startingPage "13" @default.
• W2029689076 abstract "Tenofovir (TDF) es uno de los fármacos de elección en las combinaciones de tratamiento antirretroviral de primera línea. La mayor parte de la información acerca de su eficacia y seguridad en este escenario se originó inicialmente en ensayos clínicos en los que se combinaba con no análogos de nucleósidos. Este hecho, así como la posible interacción de TDF con algunos inhibidores de proteasa (IP) y la sospecha de que esta combinación pudiera incrementar el riesgo de nefrotoxicidad, hace imprescindible analizar la experiencia clínica disponible de la combinación de TDF (asociado a emtricitabina u otro análogo de nucleósido) con un IP. En esta revisión se presentan los datos de eficacia y seguridad procedentes en su mayoría de ensayos clínicos. Tomados en su conjunto, estos estudios aportan suficiente información para poder afirmar que la combinación de TDF con IP es eficaz y segura, lo que justifica su elección en el tratamiento de primera línea o en el rescate tras el fracaso virológico. Tenofovir is one of the drugs of choice in first-line combinations of antiretroviral therapy. Most data on safety and efficacy in this scenario initially came from clinical trials in which tenofovir was combined with non-nucleoside reverse transcriptase inhibitors. Because of this, as well as the possible interaction of tenofovir with some protease inhibitors and the suspicion that this combination could increase the risk of nephrotoxicity, analysis of the clinical experience available on the combination of tenofovir (associated with emtricitabine or another nucleoside analogue) with a protease inhibitor is essential. The present review reports data on efficacy and safety, mainly from clinical trials. Taken together, these studies provide sufficient information to indicate that the combination of tenofovir and protease inhibitors is safe and effective, justifying its selection in first-line therapy or rescue therapy after virological failure." @default.
• W2029689076 created "2016-06-24" @default.
• W2029689076 creator A5000764626 @default.
• W2029689076 creator A5088415833 @default.
• W2029689076 date "2008-06-01" @default.
• W2029689076 modified "2023-09-23" @default.
• W2029689076 title "Datos clínicos II. Experiencia clínica de tenofovir en combinaciones con inhibidores de proteasa" @default.
• W2029689076 cites W1108614 @default.
• W2029689076 cites W1967167318 @default.
• W2029689076 cites W1967634644 @default.
• W2029689076 cites W1977419763 @default.
• W2029689076 cites W1995946478 @default.
• W2029689076 cites W1996702074 @default.
• W2029689076 cites W2026613816 @default.
• W2029689076 cites W2030111839 @default.
• W2029689076 cites W2045131275 @default.
• W2029689076 cites W2049080258 @default.
• W2029689076 cites W2056779298 @default.
• W2029689076 cites W2077504308 @default.
• W2029689076 cites W2086182786 @default.
• W2029689076 cites W2110937893 @default.
• W2029689076 cites W2113644342 @default.
• W2029689076 cites W2117312836 @default.
• W2029689076 cites W2135432811 @default.
• W2029689076 cites W2142982724 @default.
• W2029689076 cites W2156695548 @default.
• W2029689076 doi "https://doi.org/10.1157/13126267" @default.
• W2029689076 hasPublicationYear "2008" @default.
• W2029689076 type Work @default.
• W2029689076 sameAs 2029689076 @default.
• W2029689076 citedByCount "2" @default.
• W2029689076 crossrefType "journal-article" @default.
• W2029689076 hasAuthorship W2029689076A5000764626 @default.
• W2029689076 hasAuthorship W2029689076A5088415833 @default.
• W2029689076 hasConcept C138885662 @default.
• W2029689076 hasConcept C15708023 @default.
• W2029689076 hasConcept C159047783 @default.
• W2029689076 hasConcept C2779344132 @default.
• W2029689076 hasConcept C3013748606 @default.
• W2029689076 hasConcept C71924100 @default.
• W2029689076 hasConceptScore W2029689076C138885662 @default.
• W2029689076 hasConceptScore W2029689076C15708023 @default.
• W2029689076 hasConceptScore W2029689076C159047783 @default.
• W2029689076 hasConceptScore W2029689076C2779344132 @default.
• W2029689076 hasConceptScore W2029689076C3013748606 @default.
• W2029689076 hasConceptScore W2029689076C71924100 @default.
• W2029689076 hasLocation W20296890761 @default.
• W2029689076 hasOpenAccess W2029689076 @default.
• W2029689076 hasPrimaryLocation W20296890761 @default.
• W2029689076 hasRelatedWork W1973460911 @default.
• W2029689076 hasRelatedWork W2047134588 @default.
• W2029689076 hasRelatedWork W2096903645 @default.
• W2029689076 hasRelatedWork W2149708245 @default.
• W2029689076 hasRelatedWork W2773798272 @default.
• W2029689076 hasRelatedWork W2799465822 @default.
• W2029689076 hasRelatedWork W2908544851 @default.
• W2029689076 hasRelatedWork W3082747168 @default.
• W2029689076 hasRelatedWork W3217378250 @default.
• W2029689076 hasRelatedWork W4240838514 @default.
• W2029689076 hasVolume "26" @default.
• W2029689076 isParatext "false" @default.
• W2029689076 isRetracted "false" @default.
• W2029689076 magId "2029689076" @default.
• W2029689076 workType "article" @default.